Business Standard

India's first off-the-shelf cell therapy treatment for knee osteoarthritis

One injection will cost Rs 1.25 lakh with effects lasting for two years or more

knee
Premium

Around 35 million people suffer from knee osteoarthritis in India, and current treatment options include non-steroidal anti-inflammatory drugs (NSAIDs), Hyaluronic Acid injections, steroid injections etc

Sohini Das Mumbai
Alkem Laboratories (Alkem) and Stempeutics, a Bengaluru-based biotechnology company, are launching the first ‘off-the-shelf’ stem cell therapy - StemOne - for treating patients with osteoarthritis (OA).

Priced at Rs 1.25 lakh for a single injection, the effects can last up to two years or more in a patient progressively seeing wear and tear of the cartilage in the knee.

Alkem and Stempeutics claimed this is the first ‘allogeneic cell therapy’ product to be approved for commercial use in knee OA.

Cell therapies are typically autologous. The stem cells come from the same person who gets the transplant - meaning the patient is his/her

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 19 2022 | 6:10 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com